Blockchain

$DOP Announces Listing on 7 Exchanges including BYBIT, Kucoin, Gate.io, and Bitfinex

Tokyo, Japan, July 5th, 2024, Chainwire

 

$DOP, the token of the Data Ownership Protocol (DOP) will be available for trading in 7 major cryptocurrency exchanges such as Bybit, Kucoin, HTX, Bitfinex, Gate.io, MEXC, and WhiteBIT, starting July 5th, 2024.

The Data Ownership Protocol clarified that on Bybit, the token will be listed as $DOP1 to avoid confusion with an existing fiat coin. On KuCoin, Gate.io, Bitfinex, MEXC, and WhiteBIT, the token will be listed as $DOP.

DOP launched its mainnet six weeks ago, following a highly successful testnet phase that saw participation from 2.67 million users. In the last six months, the DOP ecosystem has grown significantly. Over 1 million DOP wallets have been opened, and assets worth more than 10 million USD have been encrypted using the protocol, showcasing the increasing demand for user-centric data ownership solutions.

“$DOP is the token of Data Ownership Protocol, a project that seeks to balance transparency and privacy on the blockchain, putting users in control of their data. The listing of our utility token marks a significant milestone and enhances our vision for the future of data ownership. We are thankful to our supporters and community who have believed in our mission from day one”, said Kohji Hirokado, co-founder of DOP and ex-core member at Cardano.

Currently, the $DOP token serves two primary functions within the ecosystem: facilitating fee payments and granting community rewards. The usage of the protocol’s data ownership features incurs fees payable in DOP tokens, creating a native demand for the token.

This system incentivizes DOP token retention while implementing a deflationary mechanism through fee burning. It also rewards network supporters via staking distributions. To date, 210,000,000 DOP tokens have been allocated for staking rewards, with over 1.1 billion DOP tokens already staked.

The listing announcement comes on the heels of Bybit’s positioning as the world’s second-largest cryptocurrency exchange by trading volume, surpassing Coinbase and trailing only Binance. Bybit’s ascent has been remarkable, with its market share doubling from 8% to 16% since October 2023.

To communicate the plans for the second half of 2024, DOP released a new roadmap following Q1’s success. The plan introduces a $5 million developer grant program, expands protocol capabilities, and plans deployment on EVM-compatible chains beyond Ethereum, reducing gas fees and reaching more users.

Moreover, the new developer SDK will enable developers to easily integrate and build dApps within the DOP ecosystem. Other objectives aim to enhance user security for managing NFTs by expanding functionality beyond ERC-20 tokens to include encryption and decryption of NFTs.

About Data Ownership Protocol (DOP)

The Data Ownership Protocol enables users to own their data. In crypto, financial data such as holdings, balances, and transaction history is publicly available on the blockchain. The mission of DOP technology is to let users decide what to share and with whom.

DOP aims to empower individuals and businesses with more control over their data through selective transparency, utilizing zero-knowledge cryptography and other advanced technologies.

For more information, users can visit Data Ownership Protocol’s: Official Website | Twitter | Linkedin

Data Ownership Protocol is the source of this content. This Press Release is for informational purposes only. The information does not constitute investment advice or an offer to invest.

 

Contact

Marketing
DOP
[email protected]

PostAd_coinrule_banner728x90

Leave a Comment

Your email address will not be published. Required fields are marked *

*

Equasens: 2024 half-year results

2024-09-27T16:00:00Z

Villers-lès-Nancy, 27 September 2024 - 6:00 p.m. (CET)

PRESS RELEASE

2024 half-year results

  • Group results impacted by weaker economic conditions and continuing investment efforts in H1:
    • Revenue: €108.0m, -4.1%
    • Current Operating Income: €20.9m, -24.1%
  • Net Profit attributable to the Group: €17.2m, -21.8%
  • Though with a profit margin that continues to be very positive:
    • Ratio of Current Operating Income (COI) to Sales: 19.3% on a reported basis and 20.0% like-for-like
H1 RESULTS (€M)2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Revenue112.6108.0-4.6-4.1%-3.7-8.3-7.4%
Current operating income (COI)27.520.9-6.6-24.1%0.0-6.7-24.3%
Net Profit22.918.1-4.8-21.0%0.0-4.8-21.1%
Net Profit attributable to the Group22.017.2-4.8-21.8%   

The financial statements for the six-month period ended 30 June 2024 were reviewed and adopted by EQUASENS' Board of Directors, chaired by Thierry Chapusot, on 27 September 2024. These interim consolidated financial statements were subject to a limited review by the Statutory Auditors.

_____

Results at 30 June 2024

H1 Current Operating Income / Division2023
reported basis
2024
reported basis
Change / Reported basisExternal growthChange / Like-for-like basis
Pharmagest18.414.1-4.3-23.5%-0.1-4.4-24.0%
Axigate Link4.64.4-0.2-4.9% -0.2-4.9%
e-Connect3.62.5-1.1-29.9% -1.1-29.9%
Medical Solutions1.30.0-1.3-100.0%0.1-1.2-92.5%
Fintech-0.4-0.10.369.3% 0.3-69.3%
Current Operating Income27.520.9-6.6-24.1%0.0-6.7-24.3%
  • PHARMAGEST division: a contraction in earnings reflecting lower sales and reinforced teams in Europe (COI/Sales: 17.2%)

The decline in the Division's operating income is mainly attributable to a reduction in sales in France in the configuration and hardware segment. In a persistently challenging economic environment, the Division continued to focus its commercial strategy on acquiring new customers and regularly rolling out new software and hardware solutions.
Despite this, recurring revenues were bolstered by the combined contribution of new SaaS offerings and contract indexation.
To accelerate the deployment of solutions in Europe, the R&D and sales teams continued to be strengthened.

  • AXIGATE LINK division: the profit margin remains high (COI/Sales: 28.6%)

Strategic investments to support the roll-out of SaaS solutions such as TitanLink for Nursing Homes in Europe, and the extension of homecare services, have temporarily weighed on the Division's results.

  • E-CONNECT division: current operating income declined in response to lower sales (COI/Sales: 45.4%)

As previously reported, H1 2023 sales and earnings were boosted by the announced discontinuation of sales of Application Reader Terminals.
The downturn in business in the first half of 2024 thus reflected the corresponding decline in sales.
Despite this unfavourable environment, the Division demonstrated its ability to adapt by maintaining a healthy profit margin based on tight cost controls.

  • MEDICAL SOLUTIONS division: a year of transition between the Ségur digital healthcare investment programme and a new software solution (COI/Sales: -)

Preparations for the Division's future involving the development of a new software platform and optimising the sales organisation led to significant investments which, in conjunction with lower sales following the end of the Ségur programme roll-out, weighed on the Division's results. Recurring revenues rose 13.7%, resulting in a gross margin of 72.8%.

  • FINTECH division: efforts to stabilise the business paid off in H1, with an improvement in earnings of €0.3m (COI/Sales: -)

Consolidated balance sheet highlights

  • Cash flow after interest and tax maintained a positive trend at €20.8m.
  • Financial investments, through acquisitions as well as capital expenditures, in particular for the EQUASENS private healthcare cloud, continued, with more than €16.0m committed in H1.
  • The net financial surplus at 30/06/2024 of €87.9m takes into account a change in presentation of IFRS 16 lease liabilities and put options for minority shareholders of €10.8m (recognised under other liabilities versus financial liabilities previously).

2024 outlook

  • The Group maintains its forecast for a return to revenue growth starting in the second half of 2024, and an acceleration in 2025 driven by current investments and an economic climate that looks set to improve, particularly for pharmacies in France.
  • The Group will continue to invest in R&D, infrastructure and sales forces in France and Europe in the second half of 2024. And while this will have a temporary impact on profitability in 2024, it should generate a return on investment from 2025 onwards.
  • With a strategy focused on patients and interoperability, the Group is ideally positioned to seize opportunities for external growth in France and Europe.

Financial calendar:

  • 1 October 2024: Presentation of H1 2024 results
  • 7 November 2024: Publication of Q3 2024 revenue
  • 6 February 2025: Publication of f Q4/FY 2024 revenue

About Group Equasens

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software and hardware solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, hospital-at-home programmes, retirement homes, health centres) in both primary and secondary care sectors.

With operations in in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).
ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about Equasens Group www.equasens.com and on LinkedIn

CONTACTS

Analyst and Investor Relations:
Chief Administrative and Financial Officer: Frédérique Schmidt
Tel: +33 (0)3 83 15 90 67 - [email protected]

Financial communication agency:
FIN’EXTENSO - Isabelle Aprile

Tel.: +33 (0)6 17 38 61 78 - [email protected]

Attachment


GlobeNewsWire News

Recent Comments